Invitrogen and Fred Hutchinson Team on Cancer Screening
News Sep 14, 2005
Invitrogen Corporation and the Fred Hutchinson Cancer Research Center have announced they have entered into a multi-year collaborative research program for the development of diagnostics and screening tools for cancer.
Under the collaboration, Invitrogen will use its expertise with the human proteome and proteomics-based approaches in combination with investigations by the lab of Sam Hanash, M.D., Ph.D., at the Hutchinson Center.
Invitrogen will utilize a variety of its proteomics technologies including its ProtoArray™ protein microarrays and extensive protein and antibody collections.
Invitrogen will also be able to license technologies produced as a result of the collaboration.
"We are honored to be working alongside pre-eminent scientists such as Dr. Hanash," said Invitrogen Chairman and CEO, Gregory T. Lucier.
"At Invitrogen we have developed and applied a comprehensive biotechnology platform to the challenge of accelerating drug discovery and disease research.”
“This collaboration is another important step in our efforts to support patient-specific research."
The collaboration is aimed at producing enabling, industry-changing technology that will change the way diseases are diagnosed and treated.
"The Fred Hutchinson Cancer Research Center is focused on preventing, diagnosing and treating cancer and other debilitating disease," explained Hanash.
"We are excited to work with an organization like Invitrogen to re-think cancer research. We believe this collaboration can push the boundaries of current cancer detection."
In 2004 Invitrogen announced a partnership with Mayo Clinic around the discovery of cancer biomarkers using its drug discovery technology portfolio.
"We believe that as our understanding of disease at a molecular level advances, early screening systems will play an important role in optimizing therapy," concluded Lucier.
"We are hopeful screening technologies from our partnership with the Hutchinson Center will allow physicians in the future to quickly diagnose disease and determine treatment options for patients before they even know they are sick."